Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122371
Filing Date
2024-11-06
Accepted
2024-11-06 16:24:40
Documents
83
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20240930.htm   iXBRL 10-Q 2584542
2 EX-4.2 algs-ex4_2.htm EX-4.2 59677
3 PDF COURTESY COPY algs-ex4_2.pdf EX-4.2 4107824
4 EX-10.2 algs-ex10_2.htm EX-10.2 27827
5 PDF COURTESY COPY algs-ex10_2.pdf EX-10.2 123004
6 EX-10.3 algs-ex10_3.htm EX-10.3 25947
7 EX-10.1(A) algs-ex10_1a.htm EX-10.1(A) 213838
8 EX-10.1(B) algs-ex10_1b.htm EX-10.1(B) 98179
9 EX-10.1(C) algs-ex10_1c.htm EX-10.1(C) 68560
10 EX-31.1 algs-ex31_1.htm EX-31.1 16829
11 EX-31.2 algs-ex31_2.htm EX-31.2 16816
12 EX-32.1 algs-ex32_1.htm EX-32.1 9295
13 EX-32.2 algs-ex32_2.htm EX-32.2 9279
14 GRAPHIC img78852433_0.jpg GRAPHIC 229241
  Complete submission text file 0000950170-24-122371.txt   15432761

Data Files

Seq Description Document Type Size
15 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT algs-20240930.xsd EX-101.SCH 1347732
86 EXTRACTED XBRL INSTANCE DOCUMENT algs-20240930_htm.xml XML 1244730
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 241431420
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)